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Abstract
Synergistic and antagonistic drug interactions are important to consider when devel-
oping mixtures of anticancer or other types of drugs. Boik, Newman, and Boik (2008) pro-
posed the MixLow method as an alternative to the Median-Eect method of Chou and Ta-
lalay (1984) for estimating drug interaction indices. One advantage of the MixLow method
is that the nonlinear mixed-eects model used to estimate parameters of concentration-
response curves can provide more accurate parameter estimates than the log linearization
and least-squares analysis used in the Median-Eect method. This paper introduces the
mixlow package in R, an implementation of the MixLow method. Results are reported for
a small simulation study.
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1. Introduction
In many branches of medicine, drugs are administered in the form of mixtures. In order to
develop new and more eective mixtures it is useful to analytically assess, with respect to the
mixture's intended eect, the interactions that occur within a mixture. Such drug interactions
can be of an additive nature, or can be antagonistic or synergistic (sub-additive or supra-
additive, respectively). The approaches used to assess drug interactions vary depending on
the design of the experiment, the expected shape of the concentration-response curve, and
other factors. For reviews see Berenbaum (1989); Greco, Bravo, and Parsons (1995); Merlin
(1994); Tallarida (2001). The approach described here is applicable to the common in-vitro
situation where within-unit and between-unit measurements are available, responses follow a
sigmoidal pattern, and ratios between drugs in a mixture are xed (that is, various dilutions of
the mixture and its component drugs are tested). While such data could be generated in many
types of experiments, the data discussed in this paper are obtained from in-vitro cytotoxicity2 An R Package for Assessing Drug Synergism/Antagonism
experiments, where cancer cells are exposed to a drug for a specied length of time (typically
72 hours) and then cell viability is indirectly measured, usually via uorescence readings after
addition of a suitable dye. Such cytotoxicity assays use multi-well incubation trays, where
each tray receives one drug or mixture, each column of the tray might receive a dierent
drug concentration, and replicate trays are tested for each drug and mixture. Responses are
typically modeled as a sigmoidal function of the drug concentration.
Several indices for assessing drug interactions have been proposed, but perhaps the most
popular one is the Loewe index. The Loewe index for a mixture is a function of the mix-
ture's concentration-response curve as well as the curves of its component drugs. Therefore,
estimating the parameters of these curves is a rst step in estimating the index. A common
method to estimate both the curve parameters and the index is the Median-Eect method
developed by Chou and Talalay (1984). This method linearizes the sigmoidal response curve
and then estimates concentration-response parameters using ordinary least squares regression.
The interaction index is estimated based on regression results. The Median-Eect method has
been criticized on several points, including the linearization step and the need for extensive
preprocessing of data Greco et al. (1995). Recently, Boik et al. (2008) proposed the MixLow
method, which is an improvement over the Median-Eect method. The MixLow method
utilizes a nonlinear mixed-eects model to more accurately estimate concentration-response
parameters. In addition, data preprocessing is minimal.
The three components of the MixLow method are a nonlinear mixed-eects model, the Loewe
index, and a method to calculate condence intervals for the index. See Boik et al. (2008) for
complete details. In some applications it is not necessary to estimate a Loewe index and only
curve parameter estimates are desired (IC50 values, for example). In such cases, estimation
of the Loewe index can be omitted. Note that the R package drm by Ritz and Streibig (2005)
also analyzes concentration-response data, but does not use a mixed-eects model to do so.
Concentration-eect data are modeled using a sigmoidal function. The utility of the sigmoidal
function stems from its simplicity (as few as two parameters) and its empirical usefulness
in modelling cytotoxicity data. For these reasons, sigmoidal functions are often used for
modelling cytotoxicity data. The MixLow method is novel in its use of a nonlinear mixed-
eects model for estimating sigmoidal curve parameters from concentration-response data,
for the purpose of estimating drug interaction indices and associated condence intervals.
This paper describes the mixlow package, an implementation of the MixLow method in R (R
Development Core Team 2009). An overview of the mathematical model is given, components
of the package are summarized, and results from a small simulation study are reported. The
package is available from the Comprehensive R Archive Network at http://CRAN.R-project.
org/package=mixlow.
2. MixLow method
Let the random variable fa signify the fraction of cells aected by a drug concentration, and
dene  = E[fa]. In some contexts,  is estimated based on the data and in other contexts
a concentration is estimated that produces a xed value of . Denote the -eective log
concentration of drug d by  d;. This is the concentration that produces a fraction aected
equal to a xed . For example, exp( d;0:2) is the concentration that inhibits proliferation of
a population by 20 percent. By convention, this is referred to as the IC20.Journal of Statistical Software 3
2.1. Basic MixLow model
The MixLow method utilizes a nonlinear mixed-eects model to estimate parameters of the
sigmoidal concentration-response curve. Responses fYd;t;wg are modeled as:
Yd;t;w = exp( + bt)(1   d;w;t) + d;t;w ; (1)
where
d;t;w = 1  
1
1 +

exp(cd;t;w)
exp( d;0:5)
d ; (2)
and the subscripts d;t;w refer to the d-th drug, t-th tray, and w-th well. In addition, d indexes
the steepness of the curve for drug d at the IC50, and cd;t;w is the log concentration of drug d in
well w and tray t. Here drug d could refer to a specic mixture or could refer to a component
drug. Model (1) can be used to estimate parameters for single drugs or a mixture, or can be
used to estimate parameters simultaneously for all component drugs and the mixture. For
treatment control wells (those that receive media, cells, and a drug concentration of zero),
d;t;w = 0. For other wells, 0 < d;t;w < 1. The expected value of exp( + bt) refers to
the expected mean response of control wells over all trays assessed, where bt is a random
deviate specic to tray t (i.e., a \tray" eect). Values fbtg are independently distributed as
bt  N(0;2
b): The error terms are independently distributed as d;t;w  N(0;f()); where f()
is a function discussed later.
The Loewe index for a mixture of n drugs is given by:
L =
n X
d=1
exp(md;)
exp( d;)
=
n X
d=1
d
exp( m;)
exp( d;)
; (3)
where md; is an unknown constant signifying the log concentration of drug d in the mixture
when the mixture is at its -eective log concentration, d is the fraction of the mixture
composed of drug d, and  m; is the -eective log concentration of the mixture. The mixture
is synergistic if L < 1, it is additive if L = 1, and it is antagonistic if L > 1. Estimate ^ L
is obtained by using estimates ^  m; and ^  d; in Equation (3). To obtain expressions for ^  m;
and ^  d;, note that if cd;t;w in (2) is equated to ^  d;, then ^ d;t;w becomes . That is,
 = 1  
1
1 +

exp( ^  d;)
exp( ^  d;0:5)
^ d : (4)
To write the Loewe index as an explicit function of ^  d;, rst solve (4) for ^  d; to obtain
^  d; = log
 

1   
 1
^ d
!
+ ^  d;0:5 : (5)4 An R Package for Assessing Drug Synergism/Antagonism
Using (3) and (5), the estimator of the index is given by
^ L =
n X
d=1
d
exp

log


1 
 1
^ m

+ ^  m;0:5

exp

log


1 
 1
^ d

+ ^  d;0:5
 : (6)
Condence intervals based on SE

log(^ L)

are obtained using the Delta method as follows:
SE

log(^ L)


0
B
@
0
@
@ log(^ L)
@ ^  
@ log(^ L)
@^ 
1
A
>
^ var
 ^  
^ 

0
@
@ log(^ L)
@ ^  
@ log(^ L)
@^ 
1
A
1
C
A
1
2
; (7)
where the superscript > refers to transpose. The term ^ var
 ^  
^ 

is obtained from the
observed information matrix, which is produced when Model (1) is t by maximizing the
likelihood function. The condence interval for ^ L is
exp

log(^ L)  tdf;1  
2 SE

log(^ L)

; (8)
where tdf;1  
2 is a multiplier obtained from the t distribution with df degrees of freedom and
 signicance level.
Equation (8) is a piecewise condence interval. In a typical linear regression setting, a si-
multaneous interval can be constructed using the Working-Hotelling procedure. If directly
applied to the Loewe index, the Working-Hotelling interval would be
exp

log(^ L) 
q
(p)F:95;p;dfSE

log(^ L)

; (9)
where p is the number of parameters used to construct the interval and df is the degrees
of freedom. The interval (9) has unknown properties, however. Model (1) is nonlinear and
contains random eects. The standard error is obtained at  using a rst-order approximation
to a linear model. Nevertheless, we can use the Working-Hotelling procedure to obtain a
rough estimate of the dierence in widths between the pointwise and continuous intervals. In
a typical two-drug experiment, the interval will be based on six parameters (  and  for each
drug and the mixture). With three replicate 96-well trays per drug (see discussion below),
the degrees of freedom will be roughly 540. Therefore, the multiplier in the continuous 95
percent interval will be larger than that in the piecewise interval by a factor of roughly
p
(p)F0:95;p;df
tdf;0:975
; (10)
or about 1.81.
2.2. Modied MixLow model
In some data sets, responses follow a sigmoidal curve but the curve appears to have a non-zero
asymptote. An example is illustrated in Figure 1. The solid curve in the gure is the sum ofJournal of Statistical Software 5
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Figure 1: Example concentration-response curve with non-zero asymptote.
the dotted sigmoidal curve and the oset from zero. This type of pattern can be modeled by
altering Model (1) to the following:
Yd;t;w = (1   d)exp( + bt)(1   0
d;w;t) + d exp( + bt) + d;t;w ; (11)
where
0
d;w;t = 1  
1
1 +

exp(cd;t;w)
exp( 0
d;0:5)
0
d
: (12)
Here, 0  d  0:5 is a drug-dependent weight, and 0,  0, and 0 all refer to the sigmoidal
curve with zero asymptote. When d = 0, Model (11) collapses to Model (1). To write the
Loewe index as a function of , ^  0
d;0:5, and ^ 0
d, an expression for ^  0
d; is obtained in a manner
similar to (5). Specically,
^  d; = log
 

1      
 1
^ 0
d
!
+ ^  0
d;0:5 : (13)
Using Model (11), and without additional assumptions, the Loewe index can only be estimated
for  < 1   max
d
(d). This is because (1   ) is not dened for values below max
d
(d) for all
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Function Purpose
trayData <- readDataFile(filename) reads data from le
mixlowData <- prepareData(trayData) prepare raw data
cellLines <- getCellLines(mixlowData) get a vector of cell line names
drugs <- getDrugs(mixlowData) get a vector of drug names
trays <- getTrays(mixlowData) get a vector of tray names
parameterDefaults <-
getNlsParameterDefaults(trays)
make data frame of parameter default
values for NLS
nlsData <- doNls(mixlowData,
parameterDefaults)
run nonlinear least-squares (NLS)
model
NlmePrintVarFunctions() print variance function options for non-
linear mixed-eects (NLME) model
nlmeData <- doNlme(mixlowData,
nlsData)
run NLME model
loeweData <- doLoewe(mixlowData,
nlmeData)
run Loewe analysis
Table 1: Functions in the mixlow package in order of use.
In Figure 1, the maximal response (E[exp(jbt)]) is 900, the half-maximal response (at con-
centration  0:5) is 450, and the asymptote occurs at a response of 100. The total response
(solid curve) is equal to the asymptotic response plus the sigmoidal response (dotted curve).
The half-maximal response of the dotted curve is 400, which occurs at a concentration  0
0:5.
3. Summary of the mixlow package
The mixlow package contains ten functions, listed in Table 1 and ordered by chronological use.
In addition, there are plot, print, and summary methods for objects trayData, mixlowData,
nlsData, nlmeData, and/or loeweData. Detailed information on the functions is available
via the help commands in R. A summary of their use and actions is provided below. To use
the mixlow package, the following six steps are performed in sequence:
1. Design the experiment, collect the data, and prepare the data le.
2. Read the data le using the function readDataFile.
3. Prepare and subset the data using the function prepareData.
4. Obtain starting values for the xed-eects parameters of the nonlinear mixed-eects
(NLME) model by using nonlinear least squares (NLS) analysis. This is done using the
function doNls.
5. Use the NLS parameters as starting values for the NLME model. The mixed-eects
model is estimated using the function doNlme.
6. Use the NLME parameters to estimate the Loewe index. This is done using the function
doLoewe.Journal of Statistical Software 7
3.1. Experimental design and preparation of the data le
The appropriate experimental design for use with the mixlow package is the \ray" design,
which has the following two characteristics:
￿ all drugs are tested individually at a variety of concentrations
￿ a mixture is made of two or more drugs and this mixture is tested at a variety of
concentrations.
As a result, ratios between component drugs of a mixture are constant over all concentrations
tested. The MixLow method will not work for checkerboard designs where ratios between
drugs in a mixture vary. Each tray should test only one drug or one mixture, and each drug
or mixture should be tested in replicate trays.
In a typical synergism experiment, two drugs and their mixture might be tested, although
the MixLow model can be used on larger mixtures. Three replicate trays might be used for
each drug and the mixture, or nine trays in total. Within each tray, 12 of the wells might be
treatment-control wells that receive cells and media but no drug, and 60 might be treatment
wells that receive drug, media, and cells. Ten dierent concentrations of the drug might be
tested in the treatment wells (6 wells per concentration). Lastly, 24 of wells might be optical
control wells (called blanks here for convenience). These can be of two types:
￿ Type bbt: optical control wells contain only media
￿ Type bbc: optical control wells contain media plus drug, and each drug concentration
tested in treatment wells is also tested in optical control wells.
The rst type is referred to here as bbt, or blanks-by-tray, and the second type is referred to
as bbc, or blanks-by-concentration. The use of blanks-by-concentration is recommended when
drugs can induce concentration-dependent responses (e.g., autouorescence). For blanks-by-
tray, treatment- and treatment-control-well responses are adjusted by subtracting the mean
response of all bbt wells in a tray. For blanks-by-concentration, a 1st to 4th degree polynomial
is t to the bbc responses and predicted values for each concentration are subtracted from
treatment- and treatment-control-well responses.
The only preprocessing of data used in the Mixlow method is subtraction of an optical correc-
tion factor for each well based on bbt or bbc responses. Relative to the variance of treatment-
well responses at each drug concentration, the variance of optical control well responses is
typically very small. Therefore, only a few bbt wells are needed per tray, or a few bbc wells
are needed per concentration. Because of the low variance, use of optical correction factors is
not likely to introduce signicant uncertainty into the model.
In many cytotoxicity experiments, a reasonable arrangement for a 96-well tray is to use the
last two rows of every column as bbc wells, use the rst six rows of the rst two columns
as treatment-control wells, and use the rst six rows of the third to twelfth columns as
treatment wells, with each column receiving a dierent drug concentration. This layout is
shown in Table 2. In the table, rx signies treatment wells and rx* signies treatment-control
wells. If there is a drug-response pattern in plates that is not related to drug concentration8 An R Package for Assessing Drug Synergism/Antagonism
C1 C2 C3 C4 C5 C6 C7 C8 C9 C10 C11 C12
R1 rx* rx* rx rx rx rx rx rx rx rx rx rx
R2 rx* rx* rx rx rx rx rx rx rx rx rx rx
R3 rx* rx* rx rx rx rx rx rx rx rx rx rx
R4 rx* rx* rx rx rx rx rx rx rx rx rx rx
R5 rx* rx* rx rx rx rx rx rx rx rx rx rx
R6 rx* rx* rx rx rx rx rx rx rx rx rx rx
R7 bbc bbc bbc bbc bbc bbc bbc bbc bbc bbc bbc bbc
R8 bbc bbc bbc bbc bbc bbc bbc bbc bbc bbc bbc bbc
Table 2: Example layout for 96-well plate.
(e.g., responses in the center wells are dierent from responses in the peripheral wells), then
a randomized concentration assignment should be employed.
To use the readDataFile function, data must be stored in a specially formatted ASCII le.
An industry standard XML format for cytotoxicity data has not yet been developed, and the
interim format described here was designed to facilitate cut-and-paste operations from plate
reader data displayed in spreadsheet format. If a XML standard format is developed in the
future, then the package can be modied to take advantage of this. Two sample data les are
included with the package and can be used as templates for constructing new data les, as
well as for testing out the capabilities of the program. One of these les contains simulated
data, and one contains data from a synergism experiment described in Boik et al. (2008).
The data le can be created in a spreadsheet (in which case it must be saved in tab-delimited
plain text format without automatic enclosing quotations). Row labels (the rst column
in a data le if a spreadsheet is used) are required, and the order of row labels must not
change from that given in the sample les. The required layout for the rst three columns
is shown in Table 3. The rst eight row labels (up to and including col) occur only once.
Other row labels are repeated for each tray. To conserve space, only three rows and two
columns are shown for the conc, label, and resp entries. Entries for the following la-
bels are optional, but all row labels, including the space labels, must still be present:
global_notes, name, Institution, email, assay, date, drug_name_full, seed_density,
assay_time, tray_notes, media, drug_solvent, solvent_drug_ratio.
The rst eight rows contain general information about the experiments and the remainder of
the le occurs in blocks, one block for each tray. Entries for tray_label and drug_name_short
should contain only digits, letters, and the underscore character. The drug_name_short entry
should consist of a unique, abbreviated drug name containing no more than 20 characters.
This will be the drug name that appears in plots and in text output. The composition entry
species the fraction of each drug in a mixture. For each drug, a string such as \drug_A =
0.5" must be given (for a hypothetical drug_A). The values provided should sum to 1.0 over
all drugs, so if a single drug is tested in a tray the string would look like \drug_A = 1". The
conc entries specify the drug concentration in each well and the label entries specify the
type of well (rx for treatment, bbt or bbc for blanks). Treatment-control wells are also given
the label rx. The resp entries specify the responses measured in each well.
The user does not need to manually alter the raw data in any way. The only exception is
when there is good reason to believe that data from certain wells in a tray are anomalies. InJournal of Statistical Software 9
Column 1 Column 2 Column 3
global_notes general notes about the experiment
name users name
Institution users institution
email users e-mail
assay the type of assay used
conc_units the units for the response
rows the number rows/tray
cols the number of columns/tray
space
tray_label the label for the rst tray
tray_replicate an identier for the replicate number
date date for this tray
cell_line cell line for this tray
drug_name_full complete drug name
drug_name_short abbreviated drug name
composition e.g., drug_1 = 0.4 e.g., drug_2 = 0.6
seed_density seeding density for well in this tray
assay_time length of incubation time
tray_notes any other notes on this tray
media type of media used
drug_solvent solvent used (DMSO, for example)
solvent_drug_ratio ratio of solvent to drug
space
conc drug conc. in row 1, col 1 drug conc. in row 1, col 2
conc drug conc. in row 2, col 1 drug conc. in row 2, col 2
conc drug conc. in row 3, col 1 drug conc. in row 3, col 2
label label for row 1, col 1 label for row 1, col 2
label label for row 2, col 1 label for row 2, col 2
label label for row 3, col 1 label for row 3, col 2
resp response in row 1, col 1 response in row 1, col 2
resp response in row 2, col 1 response in row 2, col 2
resp response in row 3, col 1 response in row 3, col 2
Table 3: Layout of the data le.
this case the responses for these wells can be replaced by periods (\.") in the resp entries
of the data le, which will cause these wells to be ignored. If desired, the excludeWells
argument of the readDataFile function can be used to exclude a list of wells from all trays.
The row and column of each cell to be excluded need to be specied in the excludeWell list.
3.2. Generating starting values for xed-eects parameters
Once a le is read using the readDataFile function, and data are subset and prepared using
the prepareData function, the next step is to generate rough estimates of concentration-
response curve parameters (,  d;0:5, log d, and d). These rough estimates will be used10 An R Package for Assessing Drug Synergism/Antagonism
as starting values for xed eects parameters in the nonlinear mixed-eects model. The
estimates are generated using the doNls function, which is a wrapper for R's nls function.
The doNls function also produces output that can be plotted, and these plots can be useful
for understanding the data and estimating parameter values graphically. An nls analysis is
performed separately on each tray.
By default, only Model (1) is estimated. If the user provides a starting value for d, then
Model (11) will also be estimated. If Model (11) is estimated, the results for Model (1) will
be compared to those for Model (11) and the one that produced the lowest BIC score will
automatically be selected. If Model (11) is estimated, the user can specify a threshold value
(lower bound) for d. If the nls function estimates a value for d that is below this threshold,
Model (1) will be selected. Final parameter estimates are obtained from the selected model.
The nls function requires starting values. As a convenience, the getNlsParameterDefaults
function can be used to generate a data frame of parameter defaults for each drug. Parameter
values of NaN indicate the following default values will be used:
￿  d;0:5 will be set at the closest tested log concentration corresponding to 1=2 the mean
of control wells
￿ std( d;0:5) will be set at the absolute value of  d;0:5=2
￿ log(d) will be set to zero
￿ std(log(d) will be set to one
￿  will be set to the log of the mean of all control wells
￿ d will be set to NaN, which indicates that a lambda term will not be used. If a lambda
term is used, its value should be set between zero and 0.5.
In order to increase the chance of model convergence, the doNls function will sample  d;0:5
and d starting values from a normal distribution with mean and standard deviation equal
to the user-supplied or default-generated values. The user can specify the number of random
samples (numRandomTries) to draw. After tting, the models are ranked by BIC scores. The
starting values for the top few models are averaged and used as starting values for a nal
model.
If verbose is set equal to TRUE, information on the various models constructed will be
printed, including a summary table that contains estimates for d,  d;0:5, , and d. These
parameters are noted as g1, p1, u1, and lambda in the printout, respectively. (Values for d
will be included only if a -model was estimated). Parameters d,  d;0:5, and  are in log
scale. The print and summary methods for the data objects returned from the prepareData,
doNls, doNlme, and doLoewe functions can also be used to examine the results.
3.3. Running the mixed-eects model
The function doNlme reads output from the NLS model and runs the NLME model. The
doNlme function is a convenience wrapper for the nlme function from the nlme package Pin-
heiro, Bates, DebRoy, Sarkar, and R Development Core Team (2009). The user supplies an
analysis argument, which can be either single or multiple. If single, each drug will beJournal of Statistical Software 11
Variance Function Analysis Type d;t;w  N(o;2
d;t;w), where d;t;w equals:
1 multiple 
2 multiple d, where parameter d is drug dependent
3 multiple E[Yd;t;w jbt]
4 multiple E[Yd;t;w jbt]d, where parameter d is drug
dependent
1 single 
2 single E[Yd;t;w jbt]
3 single E[Yd;t;w jbt]
4 single  ( + E[Yd;t;w jbt])
Table 4: Variance functions for use with the doNlme function.
analyzed separately. If multiple, all drugs will be analyzed together. The user must also
specify the variance function to be used from the list given in Table 4. If analysis is multiple,
the user can specify more than one variance function in the form of a vector, in which case
one model will be estimated for each variance function and the best model will be identied
using the BIC criterion. If analysis is single, the user must provide a list, named by drug,
which species the vector of variance functions to be used for each drug. For a given drug, if
more than one variance function is specied, one model will be estimated for each variance
function and the best model will be identied using the BIC criterion. For heteroscedastic
errors, variance function 3 (multiple drugs) or 2 (single drugs) may be appropriate in many
cases. Simpler error functions could be tried if these do not allow convergence.
As with the doNls function, if the verbose argument is set equal to TRUE, information on
the models constructed will be printed. Parameter values and standard errors are printed,
along with other information. The rc values given at the bottom of the summary for each
set of drugs is a goodness-of-t statistic similar to the r2-statistic (it is the average model
concordance correlation Vonesh, Chinchilli, and Pu 1996).
Lastly, for testing purposes, if only one tray of data is available for a drug, the function will
duplicate concentrations and responses in that tray to make two (equivalent) replicates so that
analysis can be completed. This can be used, for example, to obtain rough IC50 estimates
when only one tray is available.
3.4. Loewe analysis
After parameter estimates for the concentration-response curves have been made by the
doNlme function, these can be passed to the doLoewe function so that Loewe indices can
be estimated. The primary result from the Loewe analysis is a data frame of fraction aected
values and their corresponding Loewe index estimates. Standard errors and upper and lower
condence limits for the index at each fraction aected value are also produced. By default,
fraction aected values range from 0.02 to 0.98 (in steps of 0.01).
The output of the doLoewe function also includes a measure of the degree of statistically
signicant synergism and antagonism at each fraction aected value. For synergism, this value
is zero at any fraction aected value where the upper condence interval limit is greater than
one. Otherwise, the value is one minus the upper condence interval limit. For antagonism,
this value is zero at any fraction aected value where the lower con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less than one. Otherwise, the value is the lower condence interval limit minus one. These
values can be useful for summarizing the index over a range of fraction aected values. For
an example application, see Boik and Newman (2008).
3.5. Analysis of example data
The following code illustrates use of mixlow functions on a data set included with the package.
These data are for vincristine (vin), topotecan (topo), and their 1:1 mixture (mixture) tested
against A549 human lung cancer cells. The response curve for vincristine suggests a non-zero
asymptote.
1. Read the data le located in the mixlow/inst/exdata folder:
R> library(mixlow, lib.loc = "/home/john/MixLow_R/Naras-JB_April2010/lib")
R> dataFile <- "A549_vin_topo_data.txt"
R> trayData <- readDataFile(system.file("exdata", dataFile,
+ package = "mixlow"))
R> trays <- getTrays(data = trayData)
R> drugs <- getDrugs(data = trayData)
R> cellLines <- getCellLines(data = trayData)
2. Prepare the data:
R> mixlowData <- prepareData(trayData = trayData, trays = trays[1:9],
+ cellLines = cellLines[1])
R> summary(mixlowData)
====================== Drug Ratios ======================
tray drug cell Units rows cols mixture topo vin
1 mixture_tr1 mixture A549 ug/ml 8 12 0 0.5 0.5
2 mixture_tr2 mixture A549 ug/ml 8 12 0 0.5 0.5
3 mixture_tr3 mixture A549 ug/ml 8 12 0 0.5 0.5
4 topo_tr1 topo A549 ug/ml 8 12 0 1.0 0.0
5 topo_tr2 topo A549 ug/ml 8 12 0 1.0 0.0
6 topo_tr3 topo A549 ug/ml 8 12 0 1.0 0.0
7 vin_tr1 vin A549 ug/ml 8 12 0 0.0 1.0
8 vin_tr2 vin A549 ug/ml 8 12 0 0.0 1.0
9 vin_tr3 vin A549 ug/ml 8 12 0 0.0 1.0
3. Run NLS analysis:
R> parameterDefaults <- getNlsParameterDefaults(trays = trays[1:9])
R> parameterDefaults["vin_tr1", "param.lambda"] <- 0.2
R> parameterDefaults["vin_tr2", "param.lambda"] <- 0.2
R> parameterDefaults["vin_tr3", "param.lambda"] <- 0.2
R> nlsData <- doNls(mixlowData = mixlowData, parameterDefaults)
R> summary(nlsData)Journal of Statistical Software 13
====================== NLS Parameter Estimates ======================
tray drug cell g p u lambda
1 topo_tr1 topo A549 -0.1480674528 -4.124183 7.063048 0.0000000
2 vin_tr1 vin A549 1.3818841128 -4.392709 6.881664 0.3609912
3 mixture_tr1 mixture A549 -0.1955504845 -3.524586 7.246545 0.0000000
4 topo_tr2 topo A549 -0.3452055775 -4.753108 8.919553 0.0000000
5 vin_tr2 vin A549 0.9289258175 -4.398356 8.334986 0.1973117
6 mixture_tr2 mixture A549 -0.2026590099 -4.536981 8.379571 0.0000000
7 topo_tr3 topo A549 -0.0008971358 -4.454763 8.407929 0.0000000
8 vin_tr3 vin A549 0.4025827528 -4.746523 7.966266 0.2241574
9 mixture_tr3 mixture A549 -0.1259721587 -3.649347 8.108534 0.0000000
4. Run NLME analysis:
R> nlmeData <- doNlme(mixlowData = mixlowData, nlsData = nlsData,
+ analysis = "multiple", varFunction = 4)
R> summary(nlmeData)
====================== NLME Models ======================
-------- NLME Model item 1 --------
Nonlinear mixed-effects model fit by maximum likelihood
Model: adj_resp ~ ifelse(conc > 0, ((1 - lambda) * exp(u) *
1/(1 + (exp(log(conc) - p))^exp(g)) + exp(u) * lambda),
((1 - lambda) * exp(u) + exp(u) * lambda))
Data: dat1
Log-likelihood: -4364.634
Fixed: as.list(fixedEffects)
g.drg1 g.drg2 g.drg3 p.drg1 p.drg2 p.drg3
-0.432405263 0.662678782 -0.555394574 -4.668112915 -4.517747276 -4.193264752
u lambda.drg1 lambda.drg2 lambda.drg3
8.045593900 -0.003167944 0.187697005 -0.008620041
Random effects:
Formula: u ~ 1 | tray
u Residual
StdDev: 0.5515612 2.321458
Variance function:
Structure: Power of variance covariate, different strata
Formula: ~(fitted(.)) | drg
Parameter estimates:
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0.7224873 0.6821988 0.7323396
Number of Observations: 648
Number of Groups: 9
5. Run Loewe analysis:
R> loeweData <- doLoewe(mixlowData, nlmeData)
R> summary(loeweData)
Log Loewe index and confidence intervals:
Fraction.Affected Log.Index SE.Log.Index Lower.CI Upper.CI
1 0.02 0.3681126 0.6428543 0.1041667 1.300866
5 0.06 0.4773464 0.5203236 0.1718228 1.326131
9 0.10 0.5510492 0.4602465 0.2231895 1.360527
13 0.14 0.6154864 0.4187673 0.2704438 1.400748
17 0.18 0.6772566 0.3864187 0.3171027 1.446460
21 0.22 0.7393741 0.3595288 0.3649587 1.497907
25 0.26 0.8037164 0.3362802 0.4152500 1.555593
29 0.30 0.8717377 0.3156379 0.4690263 1.620222
33 0.34 0.9447528 0.2969569 0.5273046 1.692680
37 0.38 1.0240801 0.2798100 0.5911542 1.774055
41 0.42 1.1111240 0.2639052 0.6617495 1.865656
45 0.46 1.2074241 0.2490427 0.7403997 1.969035
49 0.50 1.3146638 0.2350945 0.8285461 2.085992
53 0.54 1.4346030 0.2219997 0.9276871 2.218513
57 0.58 1.5688290 0.2097737 1.0391356 2.368531
61 0.62 1.7180496 0.1985378 1.1633616 2.537211
65 0.66 1.8801612 0.1885850 1.2982618 2.722876
69 0.70 2.0447117 0.1805278 1.4344017 2.914697
73 0.74 2.1748904 0.1757187 1.5402012 3.071124
77 0.78 2.1292966 0.1792376 1.4975288 3.027591
R> loeweData <- doLoewe(mixlowData, nlmeData)
R> plot(loeweData)
The plot command will produce two graphs (see Figure 2), the rst of which shows the
estimated Loewe index versus fraction aected values.
NLME models can be compared by comparing their AIC and BIC values. These can be
obtained by setting the verbose argument to TRUE in the function doNlme, or by use of the
summary method on the object returned by the doNlme function. To more formally compare
two models, one can use the anova function, as demonstrated in the code snippet below.
R> nlmeData1 <- doNlme(mixlowData = mixlowData, nlsData = nlsData,
+ drugs = drugs[1:3], analysis = "multiple", varFunction = 3)
R> nlmeData2 <- doNlme(mixlowData = mixlowData, nlsData = nlsData,
+ drugs = drugs[1:3], analysis = "multiple", varFunction = 4)Journal of Statistical Software 15
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Figure 2: Loewe index for example data.
R> model1 <- nlmeData1$nlmeModels[[1]]
R> model2 <- nlmeData2$nlmeModels[[1]]
R> anova(model1, model2)
Model df AIC BIC logLik Test L.Ratio p-value
model1 1 12 8984.736 9038.423 -4480.368
model2 2 15 8759.268 8826.376 -4364.634 1 vs 2 231.4683 <.0001
4. Simulation study
Mixtures that contain more than a few drugs can be problematic in that the mixed-eects
model may not converge or may take a long time to converge if all drugs and the mixture are
analyzed together. If data are poorly behaved, convergence problems could occur for any size
mixture. If convergence becomes a problem, one alternative is to estimate the concentration-
response curve parameters separately for each drug and mixture. The user can instruct the
doNlme function to perform this type of single analysis. The disadvantage of the single-
drug approach is that control-well information is obtained from the trays of one drug only.
In contrast, control-well data from all trays are used when all drugs and the mixture are
analyzed together (multiple drug analysis). To determine if single-drug analysis makes a
large dierence in coverage of the condence intervals of the Loewe index, a simulation was
performed that compared the two approaches.
The simulation is based on Simulation C discussed in Boik et al. (2008). Model (1) was used
to generate the simulation data using the parameters listed in Table 5. These parameters are
typical for cytotoxicity assays. One thousand experiments were simulated. Each experiment
involved three drugs tested in three trays, or nine trays in total. Each tray used 14 control16 An R Package for Assessing Drug Synergism/Antagonism
Parameter Value
log(d)  0:4138
 d;0:5  3:9841 g/ml
 7.9429
b 0.388
 2.1969
variance function 4
d 0.7429
Table 5: Parameters used to generate simulation data.
wells, two bbt wells, and 80 treatment wells (8 treatment wells for each of 10 drug concen-
trations). The experiment simulated a sham mixture of a drug with itself. Therefore, the
parameters used to generate data for drug 1, drug 2, and drug 3 were identical. Data for drug
3 were taken to represent the sham mixture of a 50/50 mixture of drugs 1 and 2. As a sham
mixture, the true Loewe index is 1.0 for all fraction aected values.
Average coverage of the condence intervals for the Loewe index over all 1,000 experiments
is shown in Figure 3 as a function of fraction aected values. The nominal coverage was 0.95.
Mean coverage across all fraction aected values was 0.9612 for the multiple-drug analysis and
0.9607 for the single-drug analysis. Results suggest that coverage was near the nominal value
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Figure 3: Average coverage of the Loewe index based on 1,000 simulated experiments. The
nominal coverage coecient was 0.95.Journal of Statistical Software 17
for all fraction aected values, regardless of the type of analysis used. At fraction aected
values near 0.58, coverage for multiple-drug analysis was closer to nominal values than for
single-drug analysis (0.950 vs. 0.938, respectively). In conclusion, both types of analysis
produced excellent coverage. Multiple-drug analysis is recommended, however, if convergence
is not an issue.
5. Summary
This paper has introduced the mixlow package in R. The package should be useful for students,
researchers, and technicians who need to obtain accurate parameter estimates for sigmoidal
concentration-response curves based on in-vitro experiments. In addition, it should be useful
to those who must estimate a drug interaction index to determine if a mixture is antagonistic,
additive, or synergistic.
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